SCHEMBL5666707

SCHEMBL5666707

CCC(O)(CC)c1cc(OC)cc(OC)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.48
POLB P06746 1/20 0.40
KMT2A Q03164 1/20 0.40
CYP1A1 P04798 2/20 0.38
CYP1B1 Q16678 2/20 0.38
KDM4E B2RXH2 1/20 0.38
GAA P10253 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CYP3A4 P08684 2/20 0.37
ABL1 P00519 1/20 0.36
ABCB1 P08183 1/20 0.36
BCR P11274 1/20 0.36
TSHR P16473 1/20 0.36
AKR1B1 P15121 1/20 0.35
CYP1A2 P05177 1/20 0.34
CYP2E1 P05181 1/20 0.34
CYP2C8 P10632 1/20 0.34
CYP2D6 P10635 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2950137 0.78 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2CA1CA2
SCHEMBL5950481 0.78 ESR1 (0.39) ESR1
SCHEMBL2943735 0.77 ALDH1A1 (0.44) ALDH1A1CYP3A4CYP2C19ESR1
SCHEMBL25489581 0.77 ALDH1A1 (0.58) ALDH1A1KMT2ACYP1A1CYP1B1KDM4E
SCHEMBL3788801 0.77 ALDH1A1 (0.58) ALDH1A1KMT2ACYP1A1CYP1B1KDM4E
SCHEMBL845798 0.76 ALDH1A1 (0.50) ALDH1A1POLBKMT2ACYP1A1CYP1B1
SCHEMBL5672146 0.76 ALDH1A1 (0.50) ALDH1A1POLBKMT2ACYP1A1CYP1B1
SCHEMBL5668026 0.74 ALDH1A1 (0.48) ALDH1A1POLBKMT2ACYP1A1CYP1B1
1,3,5-Trimethoxybenzene SCHEMBL27413401 0.73 ALDH1A1 (0.69) ALDH1A1POLBKMT2ACYP1A1CYP1B1
SCHEMBL11761464 0.72 ALDH1A1 (0.37) ALDH1A1POLBKMT2ACYP1A1CYP1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1469842-A4 BICYCLIC CB2 CANNABINOID RECEPTOR LIGANDS PHARMOS CORP (US) 2006-04-26 EP disclosed
US-20050020544-A1 Bicyclic CB2 cannabinoid receptor ligands PHARMOS CORPORATION 2005-01-27 US disclosed
EP-1469842-A2 BICYCLIC CB2 CANNABINOID RECEPTOR LIGANDS PHARMOS CORPORATION (US) 2004-10-27 EP disclosed
WO-2003063758-A2 BICYCLIC CB2 CANNABINOID RECEPTOR LIGANDS PHARMOS CORPORATION (US) 2003-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020544-A1 Bicyclic CB2 cannabinoid receptor ligands CNR1, CNR2, CHRNE ALDH1A1 4401/4885POLB 2382/4885KMT2A 2650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.